跳至主要内容
临床试验/NCT01385917
NCT01385917Unknown不适用

Study of Clinical and Radiological Changes in Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping

Genethon2 个研究点 分布在 2 个国家目标入组 45 人开始时间: 2011年10月最近更新:
适应症

试验速览

阶段
不适用
发起方
Genethon
入组人数
45
试验地点
2
主要终点
PreU7-53 is a natural history study

研究概览

简要总结

PreU7-53 is a natural history study. The objective is to monitor the clinical and radiological course of upper limb muscle impairment in patients with Duchenne Muscular Dystrophy (DMD), potentially treatable with AAV-mediated exon 53 skipping.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
12 Years 至 20 Years(Child, Adult)
性别
Male
接受健康志愿者

入选标准

  • Diagnosis of Duchenne muscular dystrophy confirmed by at least genetic testing, theoretically treatable by exon 53 skipping.
  • Age between ≥ 12 and <20 years old.
  • Non ambulant patients (i;e; inability to walk more than 10 meters without any of assistance).
  • Patients covered by a national health insurance scheme.
  • Signed informed consent.

排除标准

  • Patient incapable of sitting upright in a wheelchair for at least one hour.
  • Patients with severe intellectual impairment preventing them from fully understanding the exercises to be performed.
  • Recent (less than 6 months ago) upper limb surgery or trauma This criteria is however no definitive. Patients who have undergone upper limb surgery or trauma may nonetheless be enrolled once the 6 month period is over.
  • Known immune deficiency.
  • Contraindications to NMR exams

结局指标

主要结局

PreU7-53 is a natural history study

时间窗: Every year

The objective is to monitor the clinical and radiological course of upper limb muscle impairment in patients with DMD, potentially treatable with AAV-mediated exon 53 skipping.

次要结局

未报告次要终点

研究者

发起方
Genethon
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验